SMO and fibrosis: Thus, beyond its association with the CK2α/SMO interaction, miR-55 exhibits a pleiotropic regulatory advantage by improving redox homeostasis, providing a more comprehensive mechanistic basis for its therapeutic potential against MAFLD-related fibrosis [42].